登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、本次股份质押解除情况 ■ 重要内容提示: 重庆太极实业（集团）股份有限公司（以下简称：公司）控股股东太极集团有限公司(以下简称：太极 有限)持有公司股份15,381.24万股，占公司总股本的27.89%。本次解除质押后,太极有限及其一致行动人 累计质押股份2,834.00万股，占其所持股份的18.43%，占公司总股本的5.14%。 公司于2025年12月19日接太极有限通知，获悉其所持有公司部分股份办理解除质押登记手续，具体事项 如下： 本次解除质押的股份没有用于后续质押的计划。其所持有的公司股份质押情况后续如有变动，公司将根 据相关法律法规要求及时履行信息披露义务。 二、股东累计质押股份情况 截至公告披露日，上述股东及其一致行动人累计质押股份情况如下: ■ 三、对上市公司的影响 太极有限不存在通过非经营性资金占用、违规担保、关联交易等侵害上市公司利益的情况。 太极有限资信状况较好，具备较强资金偿还能力，本次质押不存在平仓和强 ...

证券代码：600129 证券简称：太极集团 公告编号：2025-089 重庆太极实业（集团）股份有限公司 关于公司控股股东股权解押的公告 截至公告披露日，上述股东及其一致行动人累计质押股份情况如 | | 下: | | | | | | 已质押股份 | | 未质押股份情 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 情况 | | 况 | | | | | | 本次解押 | 本次解押 | 占其所 | 占公 | 已质 | 已质 | 未质 | 未质 | | 股东 | 持股数量 | 持股比 | 前累计质 | 后累计质 | 持股份 | 司总 | 押股 | 押股 | 押股 | 押股 | | 名称 | （万股） | 例 | 押数量(万 | 押数量 | 比例 | 股本 | 份中 | 份中 | 份中 | 份中 | | | | | 股) | (万股) | | 比例 | 限售 | 冻结 | 限售 | 冻结 | | | | | | | | | 股份 | 股份 | 股份 | 股份 | | | | | | | | ...

Core Viewpoint - Taiji Group's stock price closed at 17.53 yuan, reflecting a decline of 2.45% [1] Financial Performance - Southwest Securities' analyst Du Xiangyang forecasts Taiji Group's EPS for 2025, 2026, and 2027 to be 0.84 yuan, 1.11 yuan, and 1.29 yuan respectively [1] Market Trends - Taiji Group's stock has shown an overall downward trend over the past two months [1] Risks - The report highlights potential risks including price reduction from centralized procurement and the possibility of channel expansion falling short of expectations [1]

重庆市药品监督管理局关于中药材GAP符合性信息的通告 根据《国家药监局 农业农村部 国家林草局 国家中医药局关于发布〈中药材生产质量管理规范〉的公告》（2022年第22号）和《重庆市药品监督管理局实施 中药材生产质量管理规范工作指导原则》（渝药监〔2023〕36号）精神，太极集团重庆桐君阁药厂有限公司对其甘草药材供应商内蒙古塞外朔漠中药材有限 公司（合作方：重庆中药材有限公司）开展了审核检查，认为符合GAP要求。我局对太极集团重庆桐君阁药厂有限公司的GAP自评材料进行了审核，符合要 求，现予通告。 中药材GAP符合性信息 | 药品生产企业 | 中成药/饮片 | 中药 材 | 中药材种植 | | 基地面积 | 检 查 | | --- | --- | --- | --- | --- | --- | --- | | 名称 | 品种 | 品种 | 企业 | 基地地址 | （亩） | 结 | | | | | | | | 果 | | | 沉香化气片 | | | | | | | | 四君子合剂 | | | | | | | | 桔贝合剂 | | | | | | | | 龙胆泻肝片 | | | | | | | | 黄连上清丸 ...

关于全资子公司破产清算的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、国太牧业破产清算情况概述 证券代码：600129 证券简称：太极集团 公告编号：2025-088 重庆太极实业（集团）股份有限公司 由于国太牧业已停业，本次破产清算不会对公司持续经营产生重大影响。 本次指定管理人接管后，公司将丧失对国太牧业的控制权，其将不再纳入公司合并财务报表范围。本次 破产清算事项对公司本年度损益的影响最终以审计机构年度审计结果为准。 公司将持续关注该事项的后续进展情况，及时履行披露义务。敬请广大投资者谨慎决策，注意投资风 险。 四、备查文件 内蒙古自治区阿鲁科尔沁旗人民法院《决定书》（（2025）内0421破1号）。 重庆太极实业（集团）股份有限公司 重庆太极实业（集团）股份有限公司（以下简称：公司）于2025年10月23日召开第十届董事会第三十二 次会议，审议通过《关于全资子公司拟申请破产清算的议案》。由于市场竞争及外部环境变化等因素， 公司全资子公司内蒙古阿鲁科尔沁旗国太牧业有限公司（以下简称：国太牧业）经营业绩持续 ...

重庆太极实业（集团）股份有限公司（以下简称：公司）于 2025 年 10 月 23 日召开第十届董事会第三十二次会议，审议通过《关于全 资子公司拟申请破产清算的议案》。由于市场竞争及外部环境变化等 因素，公司全资子公司内蒙古阿鲁科尔沁旗国太牧业有限公司（以下 简称：国太牧业）经营业绩持续下滑，导致严重亏损，资产已不足以 偿付全部负债，为更好地聚焦主业发展，降低经营风险和减少损失， 维护公司及股东利益，公司董事会同意国太牧业向法院申请破产清算。 具体内容详见公司于 2025 年 10 月 25 日披露的《关于全资子公司拟 申请破产清算的公告》（公告编号：2025-079）。 2025 年 11 月，公司收到内蒙古自治区阿鲁科尔沁旗人民法院（以 下简称：科尔沁法院）送达的《民事裁定书》（（2025）内 0421 破 申 1 号），科尔沁法院裁定受理国太牧业的破产申请。具体内容详见 公司于 2025 年 11 月 25 日披露的《关于全资子公司破产清算的进展 公告》（公告编号：临 2025-087）。 二、国太牧业破产清算的进展情况 证券代码：600129 证券简称：太极集团 公告编号：2025-088 重庆太极实 ...

Core Viewpoint - The collaboration between Chongqing Medical University Second Affiliated Hospital and Taiji Group marks a significant step in the integration of government, medical, and enterprise sectors to modernize and industrialize traditional Chinese medicine [1][3]. Group 1: Collaboration and Objectives - The partnership aims to implement the "Healthy China" strategy and promote the revitalization of traditional Chinese medicine through the integration of clinical research capabilities and industry advantages [3]. - The focus is on creating an efficient transformation pathway from "classic prescriptions" to "modern products," enhancing the quality of the health industry in Chongqing [3][4]. Group 2: Institutional Strengths - Chongqing Medical University Second Affiliated Hospital has a strong foundation in clinical and research capabilities in traditional Chinese medicine, supported by its integrated medical center and key laboratories [3]. - The hospital has developed a closed-loop research and development system that addresses clinical needs, research breakthroughs, and result transformations [3]. Group 3: Strategic Goals - The collaboration aims to standardize and upgrade traditional Chinese medicine products, ensuring that scientifically validated and effective innovations benefit public health [3][4]. - Taiji Group emphasizes its commitment to merging traditional Chinese medicine with modern health lifestyles, focusing on making traditional formulations more convenient and accessible [4]. Group 4: Research and Development Center - A "Joint Research and Transformation Center for Traditional Chinese Medicine Formulations" will be established to focus on innovation in formulation processes, quality standards, clinical efficacy evaluation, and product development [4]. - The center aims to create a replicable and promotable model for collaborative innovation in the production, study, and application of traditional Chinese medicine [4]. Group 5: Public Engagement and Future Plans - The event included a public engagement component, allowing citizens to experience traditional Chinese medicine and receive health consultations from experts [4]. - The Chongqing Health Commission plans to continue optimizing the policy environment to support such collaborations, aiming to enhance public health and develop the local health industry [4].

Investment Rating - The report does not explicitly provide an investment rating for the gynecological drug industry in China. Core Insights - The biopharmaceutical industry in China is experiencing structural optimization, valuation recovery, and confidence rebuilding, particularly in the Hong Kong market, where the 18A system supports enterprise value discovery [2][3]. - Gynecological drug companies are characterized by specialized positioning and differentiated competition, focusing on areas such as traditional Chinese medicine, innovative treatments for gynecological tumors, and hormone drugs, showcasing strong professional images and commercialization capabilities [2][3]. Summary by Sections Capital Market Performance of China's Biopharmaceutical Sector - The A-share market has shifted from a focus on scale to sustainable development, while the Hong Kong market has attracted international capital through the 18A system, leading to a gradual rebuilding of long-term confidence in the biopharmaceutical sector [3][25]. - The A-share biopharmaceutical sector has seen a total fundraising amount of 787 billion yuan from January to October 2025, with a peak of 2,451 billion yuan in 2021, indicating a transition from a capital overheating phase to a rational development phase [13][18]. - In the Hong Kong market, the total fundraising amount reached 789 billion HKD from January to October 2025, with a peak of 1,833 billion HKD in 2020, reflecting a significant improvement in the financing environment [27][28]. Market Position Assessment of Chinese Gynecological Drug Companies - The competitive landscape of gynecological drug companies is marked by a focus on specialized fields such as innovative gynecological tumor drugs and hormone treatments, with companies establishing differentiated competitive advantages [40]. - Qianjin Pharmaceutical is recognized as a leading player in the gynecological drug market, with a strong market presence in oral gynecological inflammation traditional Chinese medicine [40]. - Heng Rui Pharmaceutical is noted for its robust pipeline in gynecological tumor treatments, with eight drugs in development as of 2024 [40]. - Xianju Pharmaceutical specializes in hormone treatments, with a focus on steroid drugs, establishing a strong professional image in the gynecological field [40]. Introduction to Representative Listed Chinese Gynecological Drug Companies - Qianjin Pharmaceutical has a significant market share of 25.8% in oral gynecological inflammation traditional Chinese medicine, demonstrating strong sales performance even in challenging market conditions [45]. - Heng Rui Pharmaceutical's research and development pipeline includes multiple innovative treatments for gynecological tumors, indicating a solid commitment to this therapeutic area [52][53]. - Xianju Pharmaceutical leverages its expertise in steroid drugs to maintain a competitive edge in the gynecological drug market, with a focus on cost-effective production and high-quality formulations [58][61].

Core Viewpoint - The announcement by China Securities Index Co., Ltd. regarding the periodic adjustment of various indices, including the CSI 300, CSI 500, and others, indicates significant changes in the sample stocks effective after the market closes on December 12, 2025 [1]. Group 1: Index Adjustments - The CSI 300 index will replace 11 sample stocks, while the CSI 500 will replace 50 stocks, and the CSI 1000 will replace 100 stocks [1]. - The CSI A50 index will see 4 stocks replaced, the CSI A100 will replace 6 stocks, and the CSI A500 will replace 20 stocks [1]. Group 2: Company-Specific Information - Tai Chi Group (600129.SH) is listed among the stocks being removed from the CSI A500 index [3]. - The company has been identified in a price risk governance notice issued by the Tianjin Municipal Medical Procurement Center, which requires companies to self-check and adjust drug prices to reasonable levels [3]. - Several products from Tai Chi Group's subsidiaries are included in a list of drugs with prices exceeding three times the minimum daily cost of similar drugs, which may lead to regulatory actions [3][4]. Group 3: Company Background - Tai Chi Group, established in 1979 and located in Chongqing, primarily engages in the pharmaceutical manufacturing industry [4]. - The company has a registered capital of 55,689.0744 million RMB and a paid-in capital of 16,684.2 million RMB [4].

Core Insights - The avian influenza concept sector experienced a decline of 0.76%, ranking among the top losers in the market, with major stocks like Zhongsheng Pharmaceutical hitting the limit down, while a few stocks like Wens Foodstuff and Weilan Biology saw gains of 1.80% each [1][2] Market Performance - The top-performing concept sectors included Titanium Dioxide with a gain of 4.31%, and Hainan Free Trade Zone with a gain of 3.54%, while the avian influenza sector was among the worst performers [1] - The avian influenza sector saw a net outflow of 784 million yuan, with 18 stocks experiencing net outflows, led by Zhongsheng Pharmaceutical with a net outflow of 684 million yuan [1] Stock Performance - Stocks with significant net outflows included: - Zhongsheng Pharmaceutical: -10.00% with a turnover rate of 18.78% and a net outflow of 683.65 million yuan - Yiling Pharmaceutical: -2.40% with a net outflow of 35.71 million yuan - Lianhuan Pharmaceutical: -1.79% with a net outflow of 25.69 million yuan - Hualan Biological: -6.60% with a net outflow of 18.13 million yuan [1] - Conversely, stocks with net inflows included: - Tiankang Biological: +1.26% with a net inflow of 16.52 million yuan - Shanghai Kaibao: -1.70% with a net inflow of 5.06 million yuan - Jinhai Biological: +0.16% with a net inflow of 3.82 million yuan [2]